CEO Marcio Souza was paid $8,708,648 in fiscal year 2025, ↓ down 35.1% from fiscal year 2024, the 86th percentile of its disclosed peer group (SEC filing 0001689548-26-000039 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,708,648 ↓ Marcio Souza total, FY2025 | 86th CEO pay percentile vs peers | 23:1 CEO-to-median pay ratio | 96.69% Say-on-pay support, latest vote |
You have just read Praxis Precision Medicines's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper PRAX reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
PRAX's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marcio Souza | $659,200 | $0 | $2,368,125 | $3,691,125 | $1,483,200 | $0 | $506,998 | $8,708,648 |
| President and Chief Executive Officer | ||||||||
| Timothy Kelly | 526,845 | 0 | 789,375 | 1,230,375 | 632,215 | 0 | 22,384 | 3,201,194 |
| Chief Financial Officer | ||||||||
| Alex Nemiroff | 456,228 | 0 | 710,438 | 1,107,338 | 547,474 | 0 | 22,305 | 2,843,783 |
| General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marcio Souza | $8,708,648 | $13,427,668 | $2,120,512 | ↓ −4,719,020 |
| Timothy Kelly | 3,201,194 | 4,044,861 | 1,023,800 | ↓ −843,667 |
| Alex Nemiroff | 2,843,783 | 3,918,084 | 843,105 | ↓ −1,074,301 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
The list of companies that name PRAX as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Dean Mitchell | Chair of the Board | $445,221 |
| Gregory Norden | Independent Director | $426,221 |
| Jeffrey Chodakewitz, M.D | Independent Director | $412,721 |
| Jill DeSimone | Independent Director | $421,221 |
| William Young | Independent Director | $418,721 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alex Nemiroff | RSU | 2025-01-10 | — | — | 11,250 | — | $710,438 |
| Marcio Souza | RSU | 2025-01-10 | — | — | 37,500 | — | 2,368,125 |
| Timothy Kelly | RSU | 2025-01-10 | — | — | 12,500 | — | 789,375 |
| Alex Nemiroff | OPTION | 2025-01-10 | — | — | 22,500 | — | 1,107,338 |
| Marcio Souza | OPTION | 2025-01-10 | — | — | 75,000 | — | 3,691,125 |
| Timothy Kelly | OPTION | 2025-01-10 | — | — | 25,000 | — | 1,230,375 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alex Nemiroff | $710,438 | $0 | $1,107,338 | 0.0% |
| Marcio Souza | 2,368,125 | 0 | 3,691,125 | 0.0% |
| Timothy Kelly | 789,375 | 0 | 1,230,375 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marcio Souza | RSU | 37,500 | — | $11,052,750 |
| Timothy Kelly | RSU | 12,500 | — | 3,684,250 |
| Alex Nemiroff | RSU | 11,250 | — | 3,315,825 |
| Timothy Kelly | RSU | 5,850 | — | 1,724,229 |
| Alex Nemiroff | RSU | 5,850 | — | 1,724,229 |
| Marcio Souza | RSU | 1,233 | — | 363,414 |
| Timothy Kelly | RSU | 400 | — | 117,896 |
| Alex Nemiroff | RSU | 300 | — | 88,422 |
| Marcio Souza | Option | 358 | 271.65 | — |
| Marcio Souza | Option | 854 | 31.8 | — |
| Marcio Souza | Option | 7,680 | 44.4 | — |
| Marcio Souza | Option | 26,042 | 43.37 | — |
| Alex Nemiroff | Option | 7,813 | 43.37 | — |
| Marcio Souza | Option | 92,501 | 56.94 | — |
| Alex Nemiroff | Option | 18,201 | 56.94 | — |
| Marcio Souza | Option | 75,000 | 63.15 | — |
| Timothy Kelly | Option | 116 | 271.65 | — |
| Timothy Kelly | Option | 540 | 31.8 | — |
| Timothy Kelly | Option | 2,715 | 44.4 | — |
| Timothy Kelly | Option | 7,813 | 43.37 | — |
| Timothy Kelly | Option | 25,000 | 63.15 | — |
| Timothy Kelly | Option | 18,201 | 56.94 | — |
| Alex Nemiroff | Option | 539 | 31.8 | — |
| Alex Nemiroff | Option | 2,181 | 44.4 | — |
| Alex Nemiroff | Option | 22,500 | 63.15 | — |
The executive compensation program is built on a strong pay-for-performance philosophy designed to align the financial interests of executive officers with those of stockholders by linking a significant portion of compensation to long-term, performance-based outcomes. The program aims to attract, motivate, and retain key personnel by providing a competitive total compensation package that emphasizes at-risk compensation tied to rigorous corporate goals and long-term value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 24,054,017 | 824,318 | 29,929 | 96.69% | Passed |
| 2025 | 2025-06-26 | 10,671,320 | 6,919,705 | 3,349 | 60.66% | Passed |
| 2024 | 2024-06-05 | 10,040,059 | 4,137,994 | 4,130 | 70.81% | Passed |
| 2022 | 2022-05-26 | 35,107,181 | 1,706,990 | 19,469 | 95.36% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 96.69%a |
| 2025 | 2025-06-26 | 60.66%b |
| 2024 | 2024-06-05 | 70.81%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $371,291 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dean MitchellIndependent · Board Chair · Compensation · Science and Technology | $86,500 | — | $358,721 | — | — | $445,221 |
| Gregory NordenIndependent · Audit (Chair) · Compensation | 67,500 | — | 358,721 | — | — | 426,221 |
| Jill DeSimoneIndependent · Audit · Nominating and Corporate Governance | 62,500 | — | 358,721 | — | — | 421,221 |
| William YoungIndependent · Compensation (Chair) · Nominating and Corporate Governance | 60,000 | — | 358,721 | — | — | 418,721 |
| Jeffrey Chodakewitz, M.DIndependent · Nominating and Corporate Governance (Chair) · Science and Technology | 54,000 | — | 358,721 | — | — | 412,721 |
| Marcio SouzaEmployee director | — | — | — | — | — | 0 |
| Stuart ArbuckleIndependent · Compensation · Science and Technology · Newly elected | — | — | — | — | — | — |
| Jeffrey KindlerIndependent · Audit · Nominating and Corporate Governance · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $330,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Praxis Precision Medicines names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Praxis Precision Medicines.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | $659,900 | $10,748,480 | $2,157,090 | $594,000 | $14,176,480 |
| 2 | Praxis Precision Medicines | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 3 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 4 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 5 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 6 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 7 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 8 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Praxis Precision Medicines | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Marcio Souza | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation”. As printed: 8,708,648. Filing ↗machine: r2 · c42 · span 326787–326796 |
| 2 | Section 01, Timothy Kelly | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation”. As printed: 3,201,194. Filing ↗machine: r5 · c42 · span 333641–333650 |
| 3 | Section 01, Alex Nemiroff | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation”. As printed: 2,843,783. Filing ↗machine: r8 · c42 · span 340485–340494 |
| 4 | Section 03, Alex Nemiroff RSU | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 367236–367243 |
| 5 | Section 03, Marcio Souza RSU | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 356624–356633 |
| 6 | Section 03, Timothy Kelly RSU | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 362081–362088 |
| 7 | Section 03, Alex Nemiroff OPTION | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 369103–369112 |
| 8 | Section 03, Marcio Souza OPTION | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 358493–358502 |
| 9 | Section 03, Timothy Kelly OPTION | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 363648–363657 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗ |
| 11 | Section 08, Dean Mitchell | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 445,221. Filing ↗machine: span 574454–574684 |
| 12 | Section 08, Gregory Norden | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 426,221. Filing ↗machine: span 575599–575829 |
| 13 | Section 08, Jill DeSimone | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 421,221. Filing ↗machine: span 573310–573540 |
| 14 | Section 08, William Young | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 418,721. Filing ↗machine: span 576743–576973 |
| 15 | Section 08, Jeffrey Chodakewitz, M.D | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 412,721. Filing ↗machine: span 570988–571244 |
| 16 | Section 08, Marcio Souza | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 08, Stuart Arbuckle | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 18 | Section 08, Jeffrey Kindler | DEF 14A | 2026-04-30 | 0001689548-26-000039 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 19 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001689548-26-000056 | Item 5.07 · say-on-pay result. As reported: 96.69% (votes for as printed: 24,054,017). Filing ↗ |
| 20 | Section 06, 2025 vote | Form 8-K | 2025-06-27 | 0001689548-25-000075 | Item 5.07 · say-on-pay result. As reported: 60.66% (votes for as printed: 10,671,320). Filing ↗ |
| 21 | Section 06, 2024 vote | Form 8-K | 2024-06-06 | 0001689548-24-000073 | Item 5.07 · say-on-pay result. As reported: 70.81% (votes for as printed: 10,040,059). Filing ↗ |
| 22 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 23 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 24 | Section 09b board cost (computed) | Computed | — | — | Cash 330,500 + equity 0 + all other 0 = 330,500, summed across the director compensation table rows.machine: formula: Σ = 330,500 |
| 25 | Avidity Biosciences, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001599901-25-000092 | CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. Filing ↗machine: r2 · c48 · span 430390–430400 |
| 26 | Praxis Precision Medicines (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001689548-26-000039 | CEO total compensation as printed in Praxis Precision Medicines's own proxy. As printed: 8,708,648. Filing ↗machine: r2 · c42 · span 326787–326796 |
| 27 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 28 | Allogene Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 29 | Beam Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 30 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 31 | Dyne Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 32 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 33 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 34 | Section 10a, Beam Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 35 | Section 10a, Dyne Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 36 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 37 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 38 | Section 10a, Allogene Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |
| 39 | Section 10a, Avidity Biosciences, Inc. reciprocity | DEF 14A | — | 0001599901-25-000092 | Avidity Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Praxis Precision Medicines. Filing ↗ |